Fast Five Quiz: COVID-19 Clinical Keys

Michael Stuart Bronze, MD

Disclosures

October 22, 2020

A study of nearly 30,000 patients taking renin-angiotensin-aldosterone system (RAAS) inhibitors, notably ACE inhibitors or ARBs, found that patients using these medications for any conditions had a lower risk for death or critical events associated with COVID-19. This large meta-analysis suggests that patients should continue with RAAS inhibitor treatment during the COVID-19 pandemic.

Women taking metformin may be at lower risk for fatal COVID-19. Among more than 6200 adults with diabetes or obesity hospitalized for COVID-19, fewer deaths were reported among women who had filled their 90-day metformin prescriptions. After adjustment for other risk factors, these women were 21%-24% less likely to die of COVID-19.

A study of patients with rheumatic and musculoskeletal diseases who developed COVID-19 found that those taking TNF inhibitors were less likely to be hospitalized. Treatment with > 10 mg of prednisone daily was associated with a higher probability of hospitalization.

Guidance from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) states that no scientific evidence supports avoidance of inhaled or oral corticosteroids in patients with COPD during the COVID-19 pandemic. A review of clinical evidence regarding the use of corticosteroids in patients with COPD or asthma concluded that the benefits of continuing inhaled or oral corticosteroid treatment outweigh the uncertain risks associated with COVID-19.

Read more about medication use during COVID-19.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....